Blue Owl Healthcare Opportunities
Overview
Blue Owl Healthcare Opportunities focuses on equity investments in mid- to late-stage, innovative biopharmaceutical and healthcare companies, while seeking to generate venture capital like returns with less duration. The strategy is complemented by investments in public securities that extends exposure to the public markets and captures ongoing value creation.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| ImmuneBiotech | May 2026 | Growth Equity | Co-investor |
| Windward Bio | May 2026 | Growth Equity | Co-investor |
| Ambrosia Bio | Mar 2026 | Series B | Lead |
| Ambrosia Biosciences Inc. | Mar 2026 | Series B | Lead |
| Mirador | Jan 2026 | Series B | Co-investor |
Key People
Michael Rees
Co-President, Founder, Head Of Dyal Capital
Rachel Craft
Managing Director - Blue Owl, GP Strategic Capital, Business Services Platform
Robert Britt
Managing Director Head Of Data Science, GP Strategic Capital
Dario Salvato
Vice President, Tech Equity Investing
Alex Santos
Principal
Ben Volok
Principal
Brittany Gold
Principal
David Hall
Principal Dyal Capital
Desmond Gordon
Compliance Principal
Francesca Kruk
Principal
Hector Del Razo
Principal
Ian Goodman
Principal
Jack Viellieu
Principal
Jared Sheiker
Principal Chief Of Staff, Real Estate
Jennifer Singer
Principal
Joseph Cortese
Principal
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
